-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Driving Real-World Evidence for Hematologic Malignancy Research – A Joint ASH RC and EU HARMONY Session

PhD Trainee
Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, health disparities research, patient-reported outcomes, Diseases, real-world evidence, Therapies, registries, Lymphoid Malignancies, Myeloid Malignancies
Monday, December 12, 2022: 4:30 PM-6:00 PM
217-219 (Ernest N. Morial Convention Center)
Chair:
William A. Wood, MD, MPH, University of North Carolina at Chapel Hill
Disclosures:
Wood: Pfizer: Research Funding; Genentech: Research Funding; Teladoc: Consultancy; Koneksa Health: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Quantum Health: Consultancy.

William A. Wood, MD, MPH

Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

Adam S. Sperling, MD, PhD

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Jesús María Hernández-Rivas, MD, PhD

Hospital Salamanca, Salamanca, Salamanca, ESP

Lars Bullinger, MD

Department of Hematology, Oncology and Tumorimmunology, Charité University Medicine Berlin, Berlin, Germany

William A. Wood, MD, MPH

Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

Samuel Rubinstein, MD

Division of Hematology, University of North Carolina-Chapel Hill, Chapel Hill, NC

Konstanze Döhner, MD

Division of Hematology and Oncology, University Hospital Ulm, Ulm, Germany

Donna S. Neuberg, ScD

Department of Data Science, Dana-Farber Cancer Institute, Boston, MA

Brian Huntly, MB ChB, FRCPath, FMedSci, PhD

Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom

Bindu Kanapuru, MD

Office of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Vienna, VA

Lars Bullinger, MD

Department of Hematology, Oncology and Tumorimmunology, Charité University Medicine Berlin, Berlin, Germany